Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on CannPal.
RELATED STOCKHEAD STORIES
News
Last Orders: The ASX saw the best IPO of 2021 so far today; but falls 0.73 per cent
News
Market highlights and 5 ASX small caps to watch today
Health & Biotech
Your ultimate guide to ASX pet stocks
News
10 at 10: These ASX stocks have hit the trail this morning
News
Rise & Shine: What you need to know before the ASX opens
Health & Biotech
A ‘game-changing’ cannabis merger: AusCann buys their way into the pet market with CannPal acquisition
Health & Biotech
CannPal Animal Therapeutics signs agreement to register doggie drug DermaCann in South Africa
Health & Biotech
The ASX small caps looking to capitalise on post-COVID trends in animal health
Health & Biotech
ASX pot stocks are getting high after TGA interim ruling
Health & Biotech
Health Kick Podcast: Cannpal has first mover advantage in the $67bn “hidden gem” animal health market
Stockhead TV
StockTalk: Animal health is a $67bn hidden gem
Health & Biotech
Animal health: The $67bn hidden gem of the global healthcare market
Health & Biotech
CannPal closes quarter with cash and commercialisation plans
Health & Biotech
Factor Therapeutics may finally have found its future — in veterinary imaging
Health & Biotech
CannPal’s doggie drug DermaCann tackles atopic dermatitis
News
North American pot stocks are on fire, Aussies still MIA
News